Literature DB >> 32376349

Sex-Based Heart Transplant Outcomes After Bridging With Centrifugal Left Ventricular Assist Devices.

Lauren V Huckaby1, Laura M Seese1, Edgar Aranda-Michel1, Michael A Mathier2, Gavin Hickey2, Mary E Keebler2, Ibrahim Sultan1, Thomas G Gleason1, Arman Kilic3.   

Abstract

BACKGROUND: Prior studies demonstrated that female sex is associated with an increased mortality after orthotopic heart transplantation (OHT). The impact of sex on OHT outcomes after bridging with newer-generation durable left ventricular assist devices (LVADs) remains unclear.
METHODS: The United Network for Organ Sharing database was queried to study OHT recipients bridged with a newer-generation LVAD (ie, HeartMate III or HeartWare) between 2010 and 2018. The primary outcome was mortality at 30 and 90-days and 1-year. Secondary outcomes included rates of posttransplant complications. Propensity score matching and Cox multivariable analysis were used to assess comorbidity-adjusted sex differences in outcomes.
RESULTS: A total of 3010 patients (76.7% male) bridged with newer-generation LVADs underwent OHT. After adjusting for relevant covariates, both age and heart failure etiology, but not sex, were independent predictors of mortality. In the matched cohorts, sex did not affect posttransplant outcomes, including renal failure, cerebrovascular events, allograft rejection, functional status, or mortality (all P > .05). Survival at 1-year after OHT was 90.5% in males and 92.8% in females (P = .058).
CONCLUSIONS: Among 3010 OHT recipients, matched females bridged with newer-generation HeartWare or HeartMate III LVADs have comparable posttransplant outcomes compared with males. Furthermore, survival at 1-year follow-up was not affected by sex; instead, it was driven by well-established risk factors including increased age, worse preoperative renal function, and heart failure etiology. These data suggest that considerable progress has been made in mitigating sex differences in heart failure outcomes in the modern era.
Copyright © 2020 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32376349      PMCID: PMC9015731          DOI: 10.1016/j.athoracsur.2020.03.096

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  13 in total

1.  Early Outcomes After Heart Transplantation in Recipients Bridged With a HeartMate 3 Device.

Authors:  Alejandro Suarez-Pierre; Cecillia Lui; Xun Zhou; Todd C Crawford; Charles D Fraser; Katherine Giuliano; Steven Hsu; Robert S Higgins; Kenton J Zehr; Glenn J Whitman; Chun W Choi; Ahmet Kilic
Journal:  Ann Thorac Surg       Date:  2019-03-14       Impact factor: 4.330

2.  Gender differences and outcomes in left ventricular assist device support: The European Registry for Patients with Mechanical Circulatory Support.

Authors:  Christina Magnussen; Alexander M Bernhardt; Francisco M Ojeda; Florian M Wagner; Jan Gummert; Theo M M H de By; Thomas Krabatsch; Paul Mohacsi; Meike Rybczynski; Dorit Knappe; Bjoern Sill; Tobias Deuse; Stefan Blankenberg; Renate B Schnabel; Hermann Reichenspurner
Journal:  J Heart Lung Transplant       Date:  2017-07-04       Impact factor: 10.247

3.  Does Small Size Matter With Continuous Flow Devices?: Analysis of the INTERMACS Database of Adults With BSA ≤1.5 m2.

Authors:  Farhan Zafar; Chet R Villa; David L Morales; Elizabeth D Blume; David N Rosenthal; James K Kirklin; Angela Lorts
Journal:  JACC Heart Fail       Date:  2016-11-02       Impact factor: 12.035

4.  Survival After Orthotopic Heart Transplantation in Patients Undergoing Bridge to Transplantation With the HeartWare HVAD Versus the Heartmate II.

Authors:  J Trent Magruder; Joshua C Grimm; Todd C Crawford; Ryan J Tedford; Stuart D Russell; Christopher M Sciortino; Glenn J R Whitman; Ashish S Shah
Journal:  Ann Thorac Surg       Date:  2016-10-17       Impact factor: 4.330

5.  Outcomes in patients with advanced heart failure and small body size undergoing continuous-flow left ventricular assist device implantation.

Authors:  Nastasya Volkovicher; Chitaru Kurihara; Andre Critsinelis; Masashi Kawabori; Tadahisa Sugiura; Marcos Manon; Andrew B Civitello; Jeffrey A Morgan
Journal:  J Artif Organs       Date:  2017-09-20       Impact factor: 1.731

6.  Clinical outcomes in sensitized heart transplant patients bridged with ventricular assist devices.

Authors:  Sumanth Kidambi; Burhan Mohamedali; Geetha Bhat
Journal:  Clin Transplant       Date:  2015-04-30       Impact factor: 2.863

7.  Gender differences in continuous-flow left ventricular assist device therapy as a bridge to transplantation: a risk-adjusted comparison using a propensity score-matching analysis.

Authors:  Alexander Weymann; Nikhil Prakash Patil; Anton Sabashnikov; Prashant N Mohite; Diana García Sáez; Mohamed Amrani; Toufan Bahrami; Fabio De Robertis; Thorsten Wahlers; Nicholas R Banner; Aron-Frederik Popov; André R Simon
Journal:  Artif Organs       Date:  2014-08-29       Impact factor: 3.094

8.  Flow cytometric evaluation of pregnancy-induced anti-HLA immunization and blood transfusion-induced reactivation.

Authors:  Jean-Michel Rebibou; Jacqueline Chabod; Dominique Alcalay; Marie-Christine Coussediere; Patrice Deteix; Guy Touchard; Isabelle Dupont; Chantal Thévenin; Jean-Marc Chalopin; Pierre Tiberghien
Journal:  Transplantation       Date:  2002-08-27       Impact factor: 4.939

9.  Gender differences in the risk of stroke during support with continuous-flow left ventricular assist device.

Authors:  Alanna A Morris; Ann Pekarek; Kris Wittersheim; Robert T Cole; Divya Gupta; Duc Nguyen; S Raja Laskar; Javed Butler; Andrew Smith; J David Vega
Journal:  J Heart Lung Transplant       Date:  2015-09-03       Impact factor: 10.247

10.  Sex-specific outcomes in patients receiving continuous-flow left ventricular devices as a bridge to transplantation or destination therapy.

Authors:  Athanasios Tsiouris; Jeffrey A Morgan; Hassan W Nemeh; Arielle Hodari; Robert J Brewer; Gaetano Paone
Journal:  ASAIO J       Date:  2014 Mar-Apr       Impact factor: 2.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.